Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin

Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. Despite aggressive therapy, survival outcomes remain unsatisfactory, especially for patients with metastatic disease or patients with a poor chemotherapy response. Chemoresistance contributes to treatment...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: De Boer, Jantine Posthuma, van Egmond, Pim W., Helder, Marco N., de Menezes, Renée X., Cleton-Jansen, Anne-Marie, Beliën, Jeroen A.M., Verheul, Henk M. W., van Royen, Barend J., Kaspers, Gert-Jan J.L., van Beusechem, Victor W.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2012
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717953/
https://ncbi.nlm.nih.gov/pubmed/23045411
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires